RO8191

RO8191 (CDM-3008), an imidazonaphthyridine compound, is an orally active and potent interferon (IFN) receptor agonist. RO8191 directly binds to IFNα/β receptor 2 (IFNAR2) and activates IFN-stimulated genes (ISGs) expression and JAK/STAT phosphorylation. RO8191 shows antiviral activity against both HCV and EMCV with an IC50 of 200 nM for HCV replicon[1]. RO8191 is a cccDNA modulator (CDM) through interferon-like activity and has anti-HBV activity[2].

Product Specifications

CAS Number

[691868-88-9]

Product Name Alternative

CDM-3008; RO4948191

UNSPSC

12352005

Hazard Statement

H315, H319

Target

HBV; HCV; IFNAR; JAK; STAT

Type

Reference compound

Related Pathways

Anti-infection; Epigenetics; Immunology/Inflammation; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt

Applications

COVID-19-anti-virus

Field of Research

Infection

Assay Protocol

https://www.medchemexpress.com/ro8191.html

Purity

99.0

Solubility

DMSO : 5 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

FC(C1=C2C=CC3=NC(C4=NN=CO4)=CN3C2=NC(C(F)(F)F)=C1)(F)F

Molecular Formula

C14H5F6N5O

Molecular Weight

373.21

Precautions

H315, H319

References & Citations

[1]Hideyuki Konishi, et al. An Orally Available, Small-Molecule Interferon Inhibits Viral Replication. Sci Rep. 2012;2:259.|[2]Yutaka Furutani, et al. An interferon-like small chemical compound CDM-3008 suppresses hepatitis B virus through induction of interferon-stimulated genes. PLoS One. 2019 Jun 12;14 (6) :e0216139.